# Approach to Outpatient Anxiety/Depression 

Kunal Patel

---

## Background

- Anxiety disorders: generalized anxiety disorder (GAD), panic
    disorder (PD), agoraphobia, social anxiety disorder (SAD), specific
    phobia

  - Some of the most prevalent psychiatric disorders

  - Age of onset varies: SAD (\~teens), PD (\~20s), GAD (broad range,
      incl. \>50)

- Depression: can refer to a mood state, syndrome, or mental disorder

  - 1-year prevalence of 10%; lifetime prevalence of 21%

  - USPTF recommends screening for depression in the general adult
      population

  - Average age of onset 30 years

  - More common in females (2:1), younger adults, lower income patients,
      and those who are divorced, separated, or widowed

## Evaluation

- Anxiety disorders

  - See table for features to elicit in history

  - Labs (not all may be necessary): CBC, BMP, TSH, UA, EKG, UDS


- Major depressive disorder (MDD)

  - See table for features to elicit in history

  - Labs (not all may be necessary): CBC, BMP, TSH, RPR, hCG, UDS, B12,
      Folate, EKG

  - Determine severity: mild, moderate, severe

      - Degree of functional impairment and disability

<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 39%" />
<col style="width: 37%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Disorder</p>
<p><em>(Symptom scales)</em></p></th>
<th>DSM-5 Criteria</th>
<th>Symptoms/features</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Generalized Anxiety Disorder</p>
<p><em>(GAD-7, Hamilton Anxiety Scale)</em></p></td>
<td><p>Excessive anxiety/worry with <strong>≥3 of 6 sx</strong>
occurring most days for <strong>&gt;6 months</strong></p>
<p>Difficult to control worry</p>
<p>Causes clinically significant distress</p>
<p>Not attributable to something else</p></td>
<td><p>Restlessness</p>
<p>Fatigued</p>
<p>Difficulty concentrating</p>
<p>Irritability</p>
<p>Muscle tension</p>
<p>Sleep disturbance</p></td>
</tr>
<tr class="even">
<td>Panic Disorder</td>
<td>Recurrent panic attacks with 1 or more attacks followed by
<strong>&gt;1 month</strong> of fear of another panic attack <strong>(≥4
sx)</strong> or maladaptive behavior</td>
<td><p>Palpitations</p>
<p>Sweating</p>
<p>Trembling</p>
<p>SOB</p>
<p>Feeling of choking</p>
<p>Chest pain</p>
<p>Nausea</p>
<p>Dizziness, lightheaded</p>
<p>Chills/heat sensation</p>
<p>Paresthesias</p>
<p>Derealization/depersonalization</p>
<p>Fear of losing control</p>
<p>Fear of dying</p></td>
</tr>
<tr class="odd">
<td>Social Anxiety Disorder</td>
<td>Fear of social or performance situations to the point where there is
impairment in function</td>
<td><p>Avoidance behavior</p>
<p>Anxiety out of proportion</p>
<p>Anxiety interfering with living</p>
<p>Fear of scrutiny, embarrassment</p>
<p>Fear not better explained by other medical condition</p></td>
</tr>
<tr class="even">
<td><p>Major Depressive Disorder</p>
<p><em>(PHQ-9, HAM-D, MDI, Montgomery-Asberg Depression Rating
Scale)</em></p></td>
<td><p><strong>≥5 sx</strong> during same <strong>2 week</strong>
period; depressed mood and/or loss of interest/pleasure must be present;
exclude sx clearly due to other medical condition</p>
<p>+</p>
<p>Sx cause significant distress, not attributable to other medical
condition or substance, not better explained by other psychotic
disorders, no history of manic or hypomanic episode</p></td>
<td><p>Depressed mood</p>
<p>Loss of interest/pleasure</p>
<p>Weight gain/loss</p>
<p>Insomnia/hypersomnia</p>
<p>Psychomotor agitation/retardation</p>
<p>Fatigue</p>
<p>Feeling worthless/guilt</p>
<p>Decreased concentration</p>
<p>Thoughts of suicide/death</p></td>
</tr>
</tbody>
</table>

## Management

- Anxiety

  - Psychotherapy and/or pharmacotherapy

- Depression

  - Mild: psychotherapy and symptom monitoring

  - Moderate: psychotherapy and pharmacotherapy

  - Severe: psych consult, psychotherapy, pharmacotherapy

## Psychotherapy

- Cognitive behavioral therapy: identifying and modifying negative
    thoughts

- Behavioral activation: scheduling positive activities and increasing
    positive interactions

- Interpersonal psychotherapy: addressing interpersonal issues in
    structured manner

- Find with psychotherapists through VUMC behavioral health referral
    or psychologytoday.com

- VA specific: First refer to PCMHI (teams for same day assessment,
    otherwise consult) and then if needed to BHIP

## Pharmacotherapy

- Good starting agents are SSRIs/SNRIs

- Choose based on patient’s specific symptoms, age, adverse effects,
    co-morbidities, and any potential drug-drug interactions

- Typically, start at low doses and titrate up every 2 weeks as needed
    until maximum dose reached

- Full effects not seen until 8-12 weeks, should wait this time before
    switching

- If no response, switch to another SSRI/SNRI

- If partial response, augment

  - Anxiety disorders: buspirone or gabapentin/pregabalin

  - MDD: Addition of second agent from different class (e.g. bupropion)

<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 23%" />
<col style="width: 23%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr class="header">
<th>Drug</th>
<th>Daily dose</th>
<th>Adverse effects</th>
<th>Other considerations</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>SSRIs</td>
<td></td>
<td>GI, sexual dysfunction, weight gain</td>
<td></td>
</tr>
<tr class="even">
<td>Citalopram</td>
<td><p>Initial: 20 mg</p>
<p>Target: 20-40 mg</p></td>
<td><p>QTc++ (Most QT prolonging)</p>
<p>Sedation</p></td>
<td>Preferred in older adults due to safety profile Black-box for doses
&gt;40 for QT prolongation</td>
</tr>
<tr class="odd">
<td>Escitalopram</td>
<td><p>Initial: 10 mg</p>
<p>Target: 10-20 mg</p></td>
<td>QTc+</td>
<td>Preferred in older adults due to safety profile the only true
serotonin selective so least off target effects, less drug-drug
interactions</td>
</tr>
<tr class="even">
<td>Fluoxetine</td>
<td><p>Initial: 20 mg</p>
<p>Target: 20-80mg</p></td>
<td><p>The only weight neutral SSRI</p>
<p>Activating</p>
<p>QTc+</p></td>
<td>Long half-life (low withdrawal risk), 1 wk wash-out when
switching</td>
</tr>
<tr class="odd">
<td>Fluvoxamine</td>
<td><p>Initial: 50 mg</p>
<p>Target: 50-200 mg</p></td>
<td>QTc+</td>
<td>Low SD, good for GAD + MDD but many drug-drug interactions, higher
doses require BID schedule</td>
</tr>
<tr class="even">
<td>Paroxetine (IR)</td>
<td><p>Initial: 20 mg</p>
<p>Target: 20-50 mg</p></td>
<td><p>Anticholinergic sedating</p>
<p>Worst SD</p>
<p>Least QTc</p></td>
<td>Short half-life (high risk of withdrawal). Not recommended in older
adults due to anticholinergic effects.</td>
</tr>
<tr class="odd">
<td>Sertraline</td>
<td><p>Initial: 50 mg</p>
<p>Target: 50-200 mg</p></td>
<td><p>QTc+, high SD</p>
<p>Activating</p></td>
<td>Preferred in older adults due to safety profile</td>
</tr>
<tr class="even">
<td>SNRIs</td>
<td></td>
<td><strong>GI, sexual dysfunction, activating</strong></td>
<td></td>
</tr>
<tr class="odd">
<td>Duloxetine</td>
<td><p>Initial: 30-60 mg</p>
<p>Target: 60-120 mg</p></td>
<td>Some weight gain</td>
<td>Good for attention and low energy, good for pain</td>
</tr>
<tr class="even">
<td>Venlafaxine</td>
<td><p>Initial: 37.5-75 mg</p>
<p>Target: 150-375 mg</p></td>
<td><p>QTc+</p>
<p>Worst SD</p>
<p>Some weight gain</p>
<p>Diastolic HTN</p></td>
<td>Risk of withdrawal, good for attention and low energy</td>
</tr>
<tr class="odd">
<td>Desvenlafaxine</td>
<td><p>Initial: 25-50 mg</p>
<p>Target: 50-100 mg</p></td>
<td>Diastolic HTN</td>
<td>Risk of withdrawal, good for attention and low energy</td>
</tr>
<tr class="even">
<td>TCAs</td>
<td></td>
<td>Anticholinergic+++, drowsiness+++, SD+++, weight gain+++</td>
<td></td>
</tr>
<tr class="odd">
<td>Amitriptyline</td>
<td><p>Initial: 25 mg</p>
<p>Target: 150-300 mg</p></td>
<td>QTc+</td>
<td>Greater risk profile than others; not first-line.</td>
</tr>
<tr class="even">
<td>Clomipramine</td>
<td><p>Initial: 25 mg</p>
<p>Target: 75-250 mg</p></td>
<td>QTc++</td>
<td>Greater risk profile than others; not first-line.</td>
</tr>
<tr class="odd">
<td>Others</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td>Buspirone</td>
<td><p>Initial: 10-15 mg</p>
<p>Target: 15-60 mg</p></td>
<td>Dizziness, HA, nervousness, drowsiness, activating</td>
<td><p>Anxiety disorders,</p>
<p>add-on for MDD (off-label)</p></td>
</tr>
<tr class="odd">
<td>Mirtazapine</td>
<td><p>Initial: 7.5-15 mg</p>
<p>Target: 15-45 mg</p></td>
<td>Drowsiness+++, anticholinergic, weight gain, dizziness, QTc</td>
<td>Good add-on with SSRI/SNRI for MDD; good for sleep, nightly
dosing</td>
</tr>
<tr class="even">
<td>Trazodone</td>
<td><p>Initial: 100 mg</p>
<p>Target: 200-400 mg</p></td>
<td>Drowsiness+++, dizziness, blurred vision, constipation, priapism,
QTc++</td>
<td>Good for sleep- typically used at lower doses for insomnia</td>
</tr>
<tr class="odd">
<td>Bupropion</td>
<td><p>Initial: 150 mg</p>
<p>Target: 150 mg BID</p></td>
<td>Dry mouth, nausea, activating, dizziness, sweating, QTc, lowers
seizure threshold</td>
<td>Good add-on with SSRI/SNRI for MDD</td>
</tr>
<tr class="even">
<td>Pregabalin</td>
<td><p>Initial: 150 mg/day</p>
<p>Target: 150-600 mg divided BID or TID</p></td>
<td>Dizziness, drowsiness, resp depression, falls, edema, SJS/rash,
DRESS</td>
<td>Anxiety disorders as adjunct (off-label), consider if another
indication (neuropathic pain)</td>
</tr>
<tr class="odd">
<td>Gabapentin</td>
<td><p>Initial: 100-300 mg/day</p>
<p>Target: 2.4g/day divided BID or TID</p></td>
<td>Dizziness, drowsiness, resp depression, falls, edema, SJS/rash,
DRESS</td>
<td>Anxiety disorders as adjunct (off-label), consider if another
indication (neuropathic pain)</td>
</tr>
</tbody>
</table>
